Pregledni rad
Therapeutic Options for the Treatment of Actinic Keratosis with Scalp and Face Localization
Nicoletta Bernardini
; “D. Innocenzi” Dermatology Unit, Polo Pontino, Sapienza University of Rome, Rome, Italy
Ilaria Proiett
; “D. Innocenzi” Dermatology Unit, Polo Pontino, Sapienza University of Rome, Rome, Italy
Ersilia Tolino
; “D. Innocenzi” Dermatology Unit, Polo Pontino, Sapienza University of Rome, Rome, Italy
Sara Zuber
; “D. Innocenzi” Dermatology Unit, Polo Pontino, Sapienza University of Rome, Rome, Italy
Alessandra Mambrin
; “D. Innocenzi” Dermatology Unit, Polo Pontino, Sapienza University of Rome, Rome, Italy
Veronica Balduzzi
; “D. Innocenzi” Dermatology Unit, Polo Pontino, Sapienza University of Rome, Rome, Italy
Anna Marchesiello
; “D. Innocenzi” Dermatology Unit, Polo Pontino, Sapienza University of Rome, Rome, Italy
Alessia Anzalone
; “D. Innocenzi” Dermatology Unit, Polo Pontino, Sapienza University of Rome, Rome, Italy
Daniela Colapietra
; “D. Innocenzi” Dermatology Unit, Polo Pontino, Sapienza University of Rome, Rome, Italy
Concetta Potenza
; “D. Innocenzi” Dermatology Unit, Polo Pontino, Sapienza University of Rome, Rome, Italy
Nevena Skroza
; “D. Innocenzi” Dermatology Unit, Polo Pontino, Sapienza University of Rome, Rome, Italy
Sažetak
Actinic keratosis (AK) is a common skin disease related to ultraviolet chronic exposure, that is now considered a
squamous cell carcinoma in situ. Primary skin cancer prevention
strategies should be recommended for high risk patients. There
is a wide spectrum of treatment options available for AKs, and
several variables should be taken into account regarding the best
therapeutic choice for each patient. The purpose of this article is
to review the current treatment strategies for AKs localized on
the face and scalp, with a focus on the practical point of view that
could be useful for choosing the best therapeutic option. The two
main therapeutic approaches will be distinguished first: lesiondirected and field-directed. Afterwards, the treatment based on
clinical type and patient comorbidity will be discussed.
Ključne riječi
Hrčak ID:
281276
URI
Datum izdavanja:
16.7.2020.
Posjeta: 262 *